Svaton, M., Fiala, O., Krakorova, G., Blazek, J., Hurdalkova, K., Barinova, M., . . . Pesek, M. (2020). Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib. Oncology letters, 20(2), p. 1376. doi:10.3892/ol.2020.11663
Chicago ZitierstilSvaton, Martin, Ondrej Fiala, Gabriela Krakorova, Jiri Blazek, Karolina Hurdalkova, Magda Barinova, Petr Mukensnabl, and Milos Pesek. "Thyroid Transcription Factor 1 and P63 Expression Is Associated With Survival Outcome in Patients With Non-small Cell Lung Cancer Treated With Erlotinib." Oncology Letters 20, no. 2 (2020): 1376.
MLA ZitierstilSvaton, Martin, et al. "Thyroid Transcription Factor 1 and P63 Expression Is Associated With Survival Outcome in Patients With Non-small Cell Lung Cancer Treated With Erlotinib." Oncology Letters 20.2 (2020): 1376.